Comparative Analysis of Primary Trigeminal Autonomic Cephalalgias

Navigating the landscape of Trigeminal Autonomic Cephalalgias (TACs) requires a structured approach to clinical assessment. Because all TACs feature unilateral pain combined with ipsilateral parasympathetic activation or sympathetic hypofunction, differentiating them relies on examining attack duration, daily frequency, specific triggers, and response to therapy.

The primary TAC conditions—Cluster Headache, Paroxysmal Hemicrania, SUNCT/SUNA, and Hemicrania Continua—can be compared across several diagnostic axes:

  • Epidemiology and Gender Distribution: Cluster headache displays a clear male predominance (1:3 to 1:7 female-to-male ratio). Paroxysmal hemicrania shows a slight female predominance (1:1 to 2.7:1). SUNCT/SUNA displays a slight male emphasis (1:1.5). Hemicrania Continua exhibits a strong female predominance (2:1 female-to-male ratio).

  • Pain Quality and Severity: Cluster headache pain is excruciating, stabbing, or boring. Paroxysmal hemicrania pain is sharp, stabbing, or throbbing. SUNCT/SUNA pain is severe to excruciating, burning, stabbing, or sharp. Hemicrania Continua presents with continuous, mild-to-severe throbbing, dull, or aching pain with periodic sharp exacerbations.

  • Temporal Dynamics: Cluster headache attacks last 15–180 minutes, occurring 1 to 8 times daily. Paroxysmal hemicrania lasts 2–30 minutes, occurring 1 to 40 times daily. SUNCT/SUNA attacks last 1–600 seconds, occurring 1 to 200 times daily. Hemicrania Continua features continuous pain persisting for months to years.

  • Triggers and Behavior: Alcohol acts as a reliable trigger for cluster headache and occasionally for paroxysmal hemicrania or hemicrania continua, but not for SUNCT. Cutaneous sensory triggers are unique to SUNCT/SUNA. Restlessness and physical agitation are common across Cluster, Paroxysmal Hemicrania, and Hemicrania Continua.

  • Indomethacin Effect: Indomethacin provides an absolute, complete therapeutic response in Paroxysmal Hemicrania and Hemicrania Continua, while offering no therapeutic benefit in Cluster Headache or SUNCT/SUNA.

Treatment selection varies according to these distinct clinical profiles. Cluster headache management combines acute high-flow oxygen or triptans with verapamil prophylaxis. SUNCT management relies on IV lidocaine for acute suppression and lamotrigine, topiramate, or gabapentin for long-term control. Indomethacin-sensitive conditions (Paroxysmal Hemicrania and Hemicrania Continua) are managed primarily with targeted indomethacin therapy.